Cancer – ACNS1723: Dabrafenib Combined with Trametinib After Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Glioma
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ACNS1723
What is the goal of this study?
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high-grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high-energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 3 and 21 years old at the time of enrollment
- Have newly diagnosed high-grade glioma with BRAFV600-mutation
- Received negative results for H3 K27M by immunohistochemistry (IHC)
- Have histologically confirmed high-grade glioma (World Health Organization [WHO] grade III or IV) including but not limited to: anaplastic astrocytoma (AA), anaplastic pleomorphic xanthoastrocytoma (aPXA), anaplastic gangliogliomas (aGG), glioblastoma (GB), and high-grade astrocytoma, not otherwise specified (NOS)
- Have had histologic verification of a high-grade glioma diagnosis. Cerebrospinal fluid (CSF) cytology by lumbar puncture must be done if clinically indicated and determined to be safe prior to study enrollment. If cytology proves positive, the patient would be considered to have metastatic disease and would, therefore, be ineligible
- Participants must have eligibility confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
What will happen if my child takes part in this study?
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.